Reglan Tardive Dyskinesia Settlement: Massachusetts Reglan Tardive Dyskinesia Injury Lawyer

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Specific Medication Risks

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy of accessible, broad-spectrum health education has empowered individuals to make informed decisions about their well-being and to recognize when medical intervention may be necessary. Within this framework, discussions of pharmaceutical therapies have naturally included both their intended benefits and potential adverse effects, fostering a balanced perspective on medical interventions. As this informational heritage evolves, a more focused examination of specific medication-related concerns becomes increasingly relevant. One such area involves the long-term use of certain prescription drugs and their association with movement disorders. In particular, exposure to Reglan (metoclopramide) has been linked to an elevated risk of developing tardive dyskinesia, a condition characterized by involuntary, repetitive body movements. This concern is especially pertinent for individuals who have undergone prolonged treatment with this medication, often prescribed for gastrointestinal motility disorders. The transition from general health awareness to this specific occupational exposure concern is natural, as it reflects a shift from population-level education to individualized risk assessment. For those who have taken Reglan over extended periods, understanding the potential for tardive dyskinesia becomes a critical component of their health management. This pivot underscores the importance of translating broad health knowledge into actionable, personal vigilance regarding medication side effects.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly prescribed to treat nausea, vomiting, and gastroparesis (https://pubmed.ncbi.nlm.nih.gov/34712535/). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, stating that metoclopramide can cause TD, a serious movement disorder that may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with the duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and healthcare providers are advised to use the drug for the shortest duration necessary, periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after the drug is discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can also be suppressed or partially masked by metoclopramide, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). While TD is often associated with long-term use, cases have been reported after even a single dose of metoclopramide, particularly in patients with underlying risk factors (https://pubmed.ncbi.nlm.nih.gov/34712535/). The mechanism involves metoclopramide's action as a dopamine D2-receptor antagonist, which can lead to extrapyramidal side effects, including TD (https://pubmed.ncbi.nlm.nih.gov/34712535/).

Legal and Settlement Considerations for Massachusetts Patients

For patients in Massachusetts who have developed TD after using Reglan, several risk and settlement-related considerations arise. The adequacy of warnings regarding the link between Reglan and TD is a central issue. The FDA-mandated boxed warning explicitly states the risk, but questions may arise about whether prescribers and patients were adequately informed, especially in cases where the drug was used for longer than recommended durations. For example, in patients with diabetic gastroparesis, the maximum recommended treatment duration is 12 weeks, and longer use should be avoided unless unavoidable, with routine monitoring for TD symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Similarly, for symptomatic gastroesophageal reflux, the maximum duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to adhere to these guidelines may contribute to liability. Settlement-related considerations for affected patients often involve the timeline between exposure to Reglan and the development of TD. While TD typically emerges after prolonged use, cases can occur after short-term exposure, complicating the assessment of causation (https://pubmed.ncbi.nlm.nih.gov/34712535/). Patients who develop TD may be entitled to compensation for medical expenses, pain and suffering, and loss of quality of life. Legal claims may focus on failure to warn, as pharmaceutical companies and healthcare providers have a duty to inform patients of known risks (https://pubmed.ncbi.nlm.nih.gov/31356297/). The medicolegal literature highlights that physicians may face liability if they fail to warn patients about adverse effects, and pharmaceutical companies may also be held accountable for inadequate warnings (https://pubmed.ncbi.nlm.nih.gov/31356297/). In Massachusetts, patients who have developed TD after using Reglan should seek legal counsel to evaluate their case. Key factors include the duration of Reglan use, the presence of any warnings provided, and the timing of symptom onset. The FDA's boxed warning serves as a critical piece of evidence, as it underscores the known risk and the need for limited use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, patients should be aware that TD can be irreversible, and early discontinuation of Reglan upon symptom onset is crucial (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of TD is not limited to long-term use, and even single-dose administration can trigger the condition in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/). In summary, Reglan use carries a well-documented risk of tardive dyskinesia, a potentially irreversible movement disorder. Patients in Massachusetts who have developed TD after using Reglan may have legal recourse, particularly if the drug was used for longer than recommended or if adequate warnings were not provided. The FDA's boxed warning and published case reports provide strong evidence of the link between Reglan and TD, supporting claims for compensation. Affected individuals should consult with an experienced injury lawyer to explore their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Reglan and how is it linked to tardive dyskinesia?

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. It carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, repetitive movements. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the settlement considerations for Massachusetts patients with Reglan-induced tardive dyskinesia?

Settlement considerations include the duration of Reglan use, adequacy of warnings, and timing of symptom onset. The FDA boxed warning is key evidence. Patients may be entitled to compensation for medical expenses, pain and suffering, and loss of quality of life. Legal claims often focus on failure to warn (https://pubmed.ncbi.nlm.nih.gov/31356297/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.